Optim.AI™ Clinical Decision Support Test
Solid Tumors and Hematologic Malignancies
ClinicalActive
Key Facts
Indication
Solid Tumors and Hematologic Malignancies
Phase
Clinical
Status
Active
Company
About KYAN Therapeutics
AI‑driven functional assay that predicts personalized cancer treatment combos from limited tumor tissue.
View full company profileTherapeutic Areas
Other Solid Tumors and Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| CAR-NK Cell Therapy | CytoImmune Therapeutics | Phase 1 |